Ran BP-5 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of Ran BP-5, a protein involved in the regulation of the Ran GTPase pathway, which plays a key role in nucleocytoplasmic transport. Ran BP-5, like other Ran-binding proteins, interacts with Ran GTPase to facilitate the movement of molecules such as RNA and proteins between the nucleus and the cytoplasm. Ran GTPase functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state, thereby regulating the transport processes critical for cellular function. Ran BP-5 is thought to modulate this transport by binding to Ran GTPase, influencing its activity in nuclear import and export processes, including the regulation of mitotic spindle assembly and cell cycle progression. Inhibitors of Ran BP-5 act by disrupting its interaction with Ran GTPase or by blocking its involvement in the transport cycle, ultimately affecting the movement of macromolecules across the nuclear envelope.
The inhibition of Ran BP-5 results in disruptions in key cellular processes that depend on efficient nucleocytoplasmic transport. By preventing Ran BP-5 from binding to Ran GTPase, these inhibitors impair the proper transport of essential molecules, leading to defects in gene expression, protein trafficking, and overall cellular function. Researchers use Ran BP-5 inhibitors to study the specific role of this protein within the broader Ran GTPase signaling network and to better understand how its regulation influences nuclear-cytoplasmic exchange and other critical cellular processes, such as mitosis and growth. These inhibitors provide a valuable tool for exploring the molecular mechanisms behind nucleocytoplasmic transport and how Ran-binding proteins like Ran BP-5 contribute to maintaining cellular homeostasis. By studying Ran BP-5 inhibitors, scientists can deepen their understanding of the dynamics of nuclear transport and the importance of Ran GTPase-associated proteins in coordinating these essential cellular functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib Mesylate targets and inhibits BCR-ABL1 tyrosine kinase, thereby reducing the proliferation of cells expressing this fusion protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor that directly inhibits ABL1 kinase activity and downstream signaling pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib, a second-generation tyrosine kinase inhibitor, selectively inhibits BCR-ABL1 tyrosine kinase and is more potent than Imatinib. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a multi-target kinase inhibitor that strongly inhibits BCR-ABL1, including the T315I mutation that confers resistance to other tyrosine kinase inhibitors. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin is a flavonoid that may inhibit ABL1 kinase activity by binding to the ATP-binding site of the enzyme. | ||||||
Bcr-abl Inhibitor | 778270-11-4 | sc-203836 | 5 mg | $149.00 | 1 | |
GNF-2 is an allosteric inhibitor that binds to the myristoyl site of ABL1, leading to inhibition of its kinase activity. | ||||||
PD 173955 | 260415-63-2 | sc-507378 | 10 mg | $320.00 | ||
PD173955 is a potent inhibitor of both SRC and ABL tyrosine kinases, preventing the phosphorylation of downstream targets. | ||||||